<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Exagen Inc — News on 6ix</title>
<link>https://6ix.com/company/exagen-inc</link>
<description>Latest news and press releases for Exagen Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/exagen-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835daa078dffbe2df123886.webp</url>
<title>Exagen Inc</title>
<link>https://6ix.com/company/exagen-inc</link>
</image>
<item>
<title>Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-first-quarter-financial-results-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-first-quarter-financial-results-on-may-11-2026</guid>
<pubDate>Mon, 27 Apr 2026 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company’s results. Conference Call & Webcast: U.S. dial-in: 877-407-08</description>
</item>
<item>
<title>Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-reports-strong-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-reports-strong-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth</description>
</item>
<item>
<title>Exagen Inc. to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will</description>
</item>
<item>
<title>Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-10-2026</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-10-2026</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial</description>
</item>
<item>
<title>Exagen Inc. Announces Select Preliminary 2025 Financial Results</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-announces-select-preliminary-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-announces-select-preliminary-2025-financial-results</guid>
<pubDate>Sun, 11 Jan 2026 20:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results Revenue Three Months EndedDecember 31, 2025 Twelve Months EndedDecember 31, 2025Total Revenue$16M to $17M $66M to $67MYear-Over-Year Growth17% to 24% 19% to 20% Other Twelve Mont</description>
</item>
<item>
<title>Exagen Inc. to Participate in Fourth Quarter Investor Conferences</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-participate-in-fourth-quarter-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-participate-in-fourth-quarter-investor-conferences</guid>
<pubDate>Tue, 11 Nov 2025 14:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: 16th Annual Craig-Hallum Alpha Select Conference Date: November 18, 2025 Location: Sheraton New York Times Square Hotel Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: November 20, 2025 Location: Westin NY Grand Central - 212 E 42nd Street New York,</description>
</item>
<item>
<title>Exagen Inc. Reports Strong Q3 2025 Results</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-reports-strong-q3-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-reports-strong-q3-2025-results</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates. Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024(Unaudited, in thousands, except ASP data) Revenue $17,244 $12,507 $49,944 $41,986 Gross margin 58.4% 55.8% 59.3% 58.7%Operating expenses $13,175 $11,644 $38,688 $34,888 Operating</description>
</item>
<item>
<title>Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-announces-acceptance-of-six-abstracts-at-2025-american-college-of-rheumatology-convergence</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-announces-acceptance-of-six-abstracts-at-2025-american-college-of-rheumatology-convergence</guid>
<pubDate>Thu, 23 Oct 2025 13:15:00 GMT</pubDate>
<description>CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds the p</description>
</item>
<item>
<title>Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-third-quarter-2025-financial-results-on-november-4-2025</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-third-quarter-2025-financial-results-on-november-4-2025</guid>
<pubDate>Tue, 21 Oct 2025 20:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 201-38</description>
</item>
<item>
<title>Exagen Inc. to Participate in Third Quarter Investor Conferences</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-participate-in-third-quarter-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-participate-in-third-quarter-investor-conferences</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Participation: Fireside Chat and 1X1 Meetings Date: Tuesday, August 12, 2025 Location: InterContinental Hotel in Boston, MA Cantor Global Healthcare Conference 2025 Participation: Fireside Chat and 1X1 Meetings Date: Wednes</description>
</item>
<item>
<title>Exagen Inc. Reports Strong Q2 2025 Results</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-reports-strong-q2-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-reports-strong-q2-2025-results</guid>
<pubDate>Tue, 29 Jul 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 (Unaudited, in thousands, exceptASP data) Revenue $17,202 $15,064 $32,700 $29,479 Gross margin 60.4% 60.1% 59.7% 59.9%Operating expenses $13,025 $11,643 $25,513 $23,244 Operating loss $(2,630) $(</description>
</item>
<item>
<title>Exagen Inc. Appoints Chas McKhann to Board of Directors</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-appoints-chas-mckhann-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-appoints-chas-mckhann-to-board-of-directors</guid>
<pubDate>Thu, 17 Jul 2025 20:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann se</description>
</item>
<item>
<title>Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-second-quarter-2025-financial-results-on-july-29-2025</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-second-quarter-2025-financial-results-on-july-29-2025</guid>
<pubDate>Tue, 15 Jul 2025 20:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by di</description>
</item>
<item>
<title>Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics</title>
<link>https://6ix.com/company/exagen-inc/news/michael-mahler-phd-joins-exagen-as-chief-scientific-officer-to-enhance-leadership-in-autoimmune-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/michael-mahler-phd-joins-exagen-as-chief-scientific-officer-to-enhance-leadership-in-autoimmune-diagnostics</guid>
<pubDate>Mon, 23 Jun 2025 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the Univers</description>
</item>
<item>
<title>Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-announces-closing-of-dollar202-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-announces-closing-of-dollar202-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares</guid>
<pubDate>Fri, 09 May 2025 20:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. Al</description>
</item>
<item>
<title>Exagen Inc. Prices Public Offering of Common Stock</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-prices-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-prices-public-offering-of-common-stock</guid>
<pubDate>Thu, 08 May 2025 12:30:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exag</description>
</item>
<item>
<title>Exagen Inc. Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-announces-proposed-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-announces-proposed-public-offering-of-common-stock</guid>
<pubDate>Wed, 07 May 2025 20:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Exage</description>
</item>
<item>
<title>Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-reports-record-q1-2025-revenue-driven-by-growth-in-average-selling-price-and-testing-volume</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-reports-record-q1-2025-revenue-driven-by-growth-in-average-selling-price-and-testing-volume</guid>
<pubDate>Mon, 05 May 2025 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates. Three Months Ended March 31, 2025 2024 (in thousands, except ASP data) Revenue $15,498 $14,415 Gross margin 58.9% 59.6%Operating expenses $12,488 $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash and cash equivalent</description>
</item>
<item>
<title>Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-announces-senior-secured-credit-facility-with-perceptive-advisors</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-announces-senior-secured-credit-facility-with-perceptive-advisors</guid>
<pubDate>Mon, 28 Apr 2025 13:00:00 GMT</pubDate>
<description>$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan credit facility of up to $75 million, with $25 million funded at closing to retire an existing debt facility and strengthen th</description>
</item>
<item>
<title>Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025</title>
<link>https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-first-quarter-2025-financial-results-on-may-5-2025</link>
<guid isPermaLink="true">https://6ix.com/company/exagen-inc/news/exagen-inc-to-announce-first-quarter-2025-financial-results-on-may-5-2025</guid>
<pubDate>Mon, 21 Apr 2025 20:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-38</description>
</item>
</channel>
</rss>